Lipid metabolism is an important topic in medical research and practice. Cholesterol and other lipids play a central role in the pathogenesis of widespread diseases such as atherosclerosis, diabetes mellitus and coronary heart disease (CHD). Heart attack and stroke (the consequences of these diseases) are among the leading causes of death in the western world1). Determining the distribution of lipoproteins in subclasses allows the individual risk of these cardiovascular diseases to be estimated more accurately.
With AXINON® lipoFIT®, numares HEALTH provides a new, extremely simple blood test enabling hospitals, physicians and researchers to perform a laboratory-based analysis of lipoprotein particles. The number of particles and cholesterol/triglyceride concentrations in classes and subclasses can be determined in high-throughput and highly standardized using numares' AXINON® lipoFIT® test system. It is optimally suited for use in Drug Discovery and Development as well as in large clinical trials.
In the blood, cholesterol and other lipids are packaged into lipoprotein particles, which are classified according to composition, size, density and physiological functions into fractions. Because of their prognostic significance for atherosclerosis, low-density lipoproteins (LDL) and high-density lipoproteins (HDL) in particular are widely known and established as standard laboratory parameters. Moreover, various subclasses can be distinguished between.
Recent research results show that considering lipoprotein subclasses, both in relation to the risk of atherosclerosis and metabolic disorders, represents a substantial advantage. These subclasses are conventionally determined through complex and less standardized ultracentrifugation methods, which limits use in clinical practice.
1) Global atlas on cardiovascular disease prevention and control. Editors: WHO; World Heart Federation; World Stroke Organization. Published 2011. Available at http://www.who.int/cardiovascular_diseases/publications/atlas_cvd/en/